Bio2 Medical touted data yesterday from the pivotal study of its Angel catheter in 163 critically ill patients with high risk of acute pulmonary embolism and contraindications to anticoagulation. The study met its safety endpoints and demonstrated a significant reduction in clinically significant and fatal pulmonary embolism, according to the company. The trial evaluated patients […]
Clinical Trials
Augmenix debuts SpaceOar in Israel
Augmenix Inc. said this week that it launched its SpaceOar hydrogel device in Israel. The Bedford, Mass.-based company’s absorbable prostate-rectum spacer is designed to reduce rectal injury during prostate radiotherapy. Get the full story at our sister site, Drug Delivery Business News.
Windtree Therapeutics touts Phase II data for inhaled surfactant
Windtree Therapeutics (NSDQ:WINT) reported data today from the 221-patient Phase IIb trial of its aerosolized KL4 surfactant for the treatment of respiratory distress syndrome in premature infants. The Aerosurf trial evaluated aerosolized KL4 surfactant administered to premature infants 28 to 32 weeks gestational age in 2 dose groups with up to 2 repeat doses, compared to […]
CardioFocus launches 3 studies of HeartLight ablation system
CardioFocus today announced the launch of 3 studies of its HeartLight endoscopic ablation system, touting that over 1,000 patients with atrial fibrillation will be enrolled across the studies. The Marlborough, Mass.-based company’s HeartLight system is designed to allow electrophysiologists to control the delivery of laser energy through direct visual guidance to isolate pulmonary veins with a […]
Synspira raises $8m for inhaled pulmonary therapies
Privately-held Synspira said today that raised $8 million from an unnamed private investor to bring its inhaled cystic fibrosis therapy into a Phase I safety study. The Boston-based company was founded earlier this year and is focused on developing inhaled therapies for pulmonary diseases, including cystic fibrosis, chronic obstructive pulmonary disease and pneumonia. Synspira holds an exclusive […]
Topical post-herpetic neuralgia treatment fails to meet primary endpoint in Phase II
Teva Pharmaceuticals (NYSE:TEVA) and Xenon Pharmaceuticals (NSDQ:XENE) said this week that the Phase II study of a topical post-herpetic neuralgia treatment did not meet its primary or secondary endpoints. The small-molecule inhibitor, TV-45070, was licensed by Xenon to Teva in December 2012. Get the full story at our sister site, Drug Delivery Business News.
NY Rep. Collins loses millions on Innate flop
Earlier this year, Rep. Chris Collins’ (R-NY) 16.8% stake in Innate Immunotherapeutics (ASX:IIL) was worth $45.5 million. But since the Australian biotech’s lead drug failed in a 93-patient trial this week, shares in the company dropped to 4¢ apiece and Collins’ holdings are now valued at just $1.5 million. As the company’s largest investor and […]
Study: Researchers develop new spectroscopy probe, claim 100% cancer detection rate
Researchers at the University of Montreal Hospital Research Center say they have developed a multimodal optical spectroscopy probe that could provide patients with common widespread forms of cancer longer life expectancies and lower risk of recurrence. The team, which began work on the probe in 2015, have refined the invention and designed a new device […]
Researchers make steps towards closed-loop DBS system for essential tremor, Parkinsons
Researchers at the University of Washington say they developed an advanced deep brain stimulation system designed to treat essential tremor without constantly being “on,” allowing for longer battery life and better treatment. The system utilizes electrodes on top of the brain to sense movement in parts of the body that experience essential tremor, alongside a […]
Study: Electronic reminders, monitoring don’t improve adherence, results for AMI patients
Interventions involving wireless electronic pill bottles, financial incentives and social support may not help improve compliance or clinical outcomes for patients who’ve experienced acute myocardial infarctions, according to a new study. The study, published in the Journal of the American Medical Association this week, aimed to explore the use of wireless tech and behavioral economic […]
InVivo touts 2 patient recoveries in Inspire trial
InVivo Therapeutics (NSDQ:NVIV) said today that 2 patients in the Inspire trial of its neuro-spinal scaffold have shown significant improvements in motor recovery assessments. The Cambridge, Mass.-based company’s neuro-spinal scaffold is designed to be surgically implanted following acute spinal cord injuries to act as a physical substrate for nerve sprouting. InVivo said that the 2 patients […]